VCM
ZNTL icon

Versant Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Versant Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46
Closed -$725 – 2015
2024
Q1 		$725 Buy
+46
New +$633 ﹤0.01% 1614

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Versant Capital Management's ZNTL Position: Q2 2024 in Review

Versant Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 46 shares — an estimated $725 sold.

Versant Capital Management first reported a position in ZNTL in Q1 2024 and held it in 1 quarter. The position peaked at $725 in Q1 2024. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • Versant Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Versant Capital Management sold 46 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $725.
  • Versant Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Versant Capital Management's Zentalis Pharmaceuticals position peaked at $725 in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Versant Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.